Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Generate Biomedicines, SpaceX, and 370+ companies. 5-min read every Tuesday.
AI-first drug company using generative biology to design novel protein therapeutics.
| Industry | Biotechnology |
| Stage | Series A |
| IPO Status | Private |
| Valuation | $1.2B |
| Total Funding | $150M |
| Headquarters | Cambridge, MA |
Aerospace and defense company with proprietary reusable rocket technology. Confidential S-1 filed April 2026 targeting $75B Nasdaq IPO at $1.75T valuation. $20B projected 2026 revenue, $14B EBITDA. Government contracts with NASA and DoD.
| Industry | Aerospace & Defense |
| Stage | Pre-IPO |
| IPO Status | Private |
| Valuation | $1.75T |
| Total Funding | $11.9B |
| Headquarters | Hawthorne, CA |
Generate Biomedicines is valued at $1.2B. SpaceX is valued at $1.75T. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Generate Biomedicines has raised $150M. SpaceX has raised $11.9B.
Generate Biomedicines is currently private. SpaceX is currently private. Track both on TechStackIPO for S-1 filings and IPO announcements.
Generate Biomedicines operates in Biotechnology, while SpaceX operates in Aerospace & Defense.
Generate Biomedicines is a Biotechnology company valued at $1.2B with $150M raised. SpaceX is a Aerospace & Defense company valued at $1.75T with $11.9B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Generate Biomedicines and SpaceX through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.